Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reproductive Endocrinology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Reproductive Endocrinology. Displaying page 1 of 1.
    EudraCT Number: 2020-002612-52 Sponsor Protocol Number: LUCAS Start Date*: 2021-02-19
    Sponsor Name:Department of Endocrinology, Rigshospitalet
    Full Title: A randomized, double-blinded, clinical, placebo-controlled trial on the effects of therapy with Letrozole and hUman Choriongonadotropin in male hypogonadism induced by illicit use of Anabolic andro...
    Medical condition: Male hypogonadism related to illicit use of anabolic androgenic steroids
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10058359 Hypogonadism PT
    21.0 10038604 - Reproductive system and breast disorders 10021926 Infertility PT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016921-32 Sponsor Protocol Number: HSJD-OB-TRP Start Date*: Information not available in EudraCT
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: A phase II, randomized, double-blind, placebo-controlled, in parallel groups clinical trial to assess the safety and efficacy of dietary supplementation with tryptophan to achieve weight loss, and ...
    Medical condition: obesity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004266-15 Sponsor Protocol Number: ARYHM-1 Start Date*: 2012-01-18
    Sponsor Name:RMC, Skåne University Hospital
    Full Title: Androgen replacement in young hypogonadal men: a 2 year randomized, double-blind placebo controlled study
    Medical condition: Target population: Male hypogonadism (testosterone deficiency) As end points Bone mineralisation Body composition Markers of insulin sensitivity and cardiovascular disease Lipid profile H...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10067734 Testosterone deficiency LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002300-13 Sponsor Protocol Number: CCR13001,CF111/205 Start Date*: 2013-11-05
    Sponsor Name:CHEMO France
    Full Title: A study to evaluate the effect on the endometrium of a new formulation containing 4 mg drospirenone (Drospirenone 4 mg film-coated tablet) administered over a period of 13 cycles. A monocentric, op...
    Medical condition: Assessing the endometrial safety of an oral test preparation containing 4 mg drospirenone, which is usually used as contraceptive.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10042613 - Surgical and medical procedures 10030970 Oral contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-002553-29 Sponsor Protocol Number: kk-2013 Start Date*: 2013-08-22
    Sponsor Name:Jens Sønksen
    Full Title: Metabolic changes due to iatrogenic hypogonadism in patients with prostate cancer: orchiectomy vs. triptorelin
    Medical condition: Men with prostate cancer where lifelong castration is indicated
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    16.0 100000004865 10067329 Chemical male castration LLT
    16.0 100000004865 10049629 Male operative castration LLT
    16.0 10027433 - Metabolism and nutrition disorders 10052066 Metabolic syndrome PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006220-40 Sponsor Protocol Number: 2022-0101-01 Start Date*: 2022-06-30
    Sponsor Name:Hvidovre Hospital, Department of Gynecology
    Full Title: Double-blinded randomized placebo-controlled trial on tacrolimus in women with an euploid pregnancy loss and PCOS and/or thyroid autoimmunity
    Medical condition: Polycystic ovarian syndrome and/or thyroid autoimmunity in combination with an euploid pregnancy loss
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    21.0 100000004848 10069094 Thyroid peroxidase antibody positive LLT
    20.1 100000004848 10060326 Thyroglobulin antibody positive LLT
    22.1 100000004868 10072314 Pregnancy loss LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001802-27 Sponsor Protocol Number: F002MH0218_1 Start Date*: 2019-04-16
    Sponsor Name:University Hospital Wuerzburg
    Full Title: A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma.
    Medical condition: Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10001353 Adrenal gland disorders HLGT
    20.0 10014698 - Endocrine disorders 10001341 Adrenal cortical hyperfunctions HLT
    20.0 10014698 - Endocrine disorders 10001376 Adrenal neoplasms HLT
    20.0 100000004864 10001378 Adrenal neoplasms malignant HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA